Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 11
  • Journal CiteScore: 0.91
  • Journal Impact Factor: 0.6
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

The impact of rosuvastatin and omeg-3 on the antitumoral activity and cardiotoxicity of doxorubicin compared to captopril effect in experimentally-induced hepatocellular carcinoma in mice

Joint Event on 36th World Cancer Conference & 3rd Edition of International Conference on Colorectal Cancer
October 11-13, 2018 Zurich, Switzerland

Ibrahim El-Sayed

Cairo University, Egypt

Scientific Tracks Abstracts: Arch Cancer Res


Background: Despite its usefulness as an antineoplastic agent, doxorubicin (DOX) has been associated with the development of acute and chronic cardiotoxicity. Aim: The present study for the first time was undertaken to evaluate and compare the potential antitumoral effects of three drugs; (captopril, rosuvastatin and omega 3) in combination with DOX against diethylnitrosamine (DEN)-induced hepatocellular (HCC) in mice, in an attempt to achieve an improved antitumoral effect devoid of cardiotoxicity. Methods: The effect of combined treatments was evaluated by analyzing cell viability in vitro, studying tumor apoptosis (Bcl-X and Bak) and angiogenesis (VEGF) in vivo, assessing cardiac inflammation (TNF-α ) and oxidative stress (MDA,GSH, SOD), and evaluating variations of heart weight/body weight ratio as a general indicator of animal health status. Histopathological assessement of liver and heart were also performed. Results: Compared to the DEN group, administration of doxorubicin (12 mg/kg ip) resulted in a significant increment in Bak expression and a significant decrease of hepatic VEGF level. Furthermore, captopril (25 mg/kg, po), rosuvastatin (20 mg/kg, po) and omega-3 (1gm/kg, po) treated groups were shown to have more pronounced reduction of hepatic VEGF measured. Marked cardioprotection was noticed with the combination regimen. Conclusion: The antitumoral, apoptotic and antiangiogenic effects demonstrated by the combined treatment with rosuvastatin, captopril or omega 3 and DOX, is further emphasized by lack of toxicity. The most promising results were obtained with rosuvastatin and captopril treatment. These data raise important issues that may impact how these drugs can best be included in chempotherapy regimens.

Biography :


[email protected]